{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-256326","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.345836+00:00","generated_at":"2026-05-17T01:41:33.292909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TransMedics Q3 revenue $143.8M (+32% YoY); raises FY2025 guidance to $595-605M","bullets":["Revenue $143.8M, up 32% vs Q3 2024; net income $24.3M ($0.66 diluted EPS) vs $4.2M a year ago.","Gross margin improved to 59% from 56%; cash balance $466.2M as of Sept 30.","FY2025 revenue guidance raised to $595-605M (midpoint $600M, 36% growth); prior range was $585-605M.","Announced strategic collaboration with Mercedes-Benz to deploy V-Class vehicles for organ transport in Italy.","Owned 21 aircraft as of Sept 30 (22 as of Oct 29); OCS growth driven by NOP and aviation fleet expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-256326","json":"https://secwatch.observer/filing/0001193125-25-256326.json","markdown":"https://secwatch.observer/filing/0001193125-25-256326.md","text":"https://secwatch.observer/filing/0001193125-25-256326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/0001193125-25-256326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/tmdx-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:41:33.292909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}